Group 1 - A new company named Zhong Sai Bai Tai Biotechnology (Hangzhou) Co., Ltd. has been established, focusing on artificial intelligence application software development [1] - The company's business scope also includes general mechanical equipment installation services, software outsourcing services, and information system integration services [1] - The company is jointly held by Jiete Biological (688026) and other stakeholders [1]

Core Viewpoint - Recently, Zhongsaibaitai Biotechnology (Hangzhou) Co., Ltd. was established, focusing on artificial intelligence application software development and other related services [1] Company Summary - Zhongsaibaitai Biotechnology (Hangzhou) Co., Ltd. has a business scope that includes artificial intelligence application software development, general machinery installation services, software outsourcing services, and information system integration services [1] - The company is jointly held by Jiete Biotechnology and other stakeholders [1]

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock price performance [6][11]. Group 1: Board Meeting Decisions - The fourth board meeting of the company was held on November 21, 2025, with all seven directors present, and the decision was made to not adjust the conversion price of the "Jiet Bio" convertible bonds [1][2]. - The decision was made with a vote of 4 in favor, 0 against, and 0 abstentions [2]. Group 2: Convertible Bond Details - The "Jiet Bio" convertible bonds were issued in 2022, with a total of 4.4 million bonds at a face value of 100 RMB each, raising a total of 440 million RMB [8]. - The initial conversion price was set at 48.23 RMB per share, which has been adjusted multiple times due to various corporate actions [9]. Group 3: Price Adjustment Clause - The downward adjustment clause for the conversion price is triggered when the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [10]. - As of the announcement date, the stock price had indeed triggered this clause, but the board decided against making any adjustments for the next three months [11].

Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 25th meeting of the fourth board of directors on November 21, 2025, via telecommunication, where it reviewed the proposal regarding not adjusting the conversion price of "Jiet Convertible Bonds" [1] - For the year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other businesses account for 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.4 billion yuan [1]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-068 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于不向下修正"洁特转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、转股价格调整/修正依据 （一）"洁特转债"基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，广州洁特生物过滤股份有限公司（以下简称"公司"）向不特定对象共计发 行 440.00 万张，每张面值为人民币 100 元，按面值发行。本次发行合计募集资 金人民币 44,000.00 万元。经上海证券交易所《自律监管决定书》（[2022]203 号 文）同意，公司 44,000.00 万元可转换公司债券已于 2022 年 8 月 2 日起在上海证 券交易所挂牌交易，债券简称"洁特转债"，债券代码"11 ...

一、审议通过《关于不向下修正"洁特转债"转股价格的议案》 具体内容详见公司同日刊载于《中国证券报》《证券时报》《上海证券报》 《证券日报》及上海证券交易所（www.sse.com.cn）的《关于不向下修正"洁特 转债"转股价格的公告》（公告编号：2025-068）。 表决结果：4 票同意，0 票反对，0 票弃权。 | 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-067 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 第四届董事会第二十五次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）第四届董事会第二十 五次会议于 2025 年 11 月 21 日以通讯的方式召开，会议通知已于 2025 年 11 月 14 日通过电子邮件的方式送达全体董事。本次会议应出席董事 7 人，实际出席 董事 7 人。会议由董事长袁建华主持，会议召开符合有关法律、法规、规章和 ...

Core Insights - The company, Jiet Bio (688026.SH), has reported an overall capacity utilization rate of approximately 60% [1] - A new factory has partially commenced operations, but some equipment and production lines are still in the debugging phase, with full production dependent on order volume [1] - The company's main products include over 80 categories of biological laboratory consumables, such as cell culture and liquid handling products, which have a strong sales market [1]

Core Viewpoint - The company is potentially triggering a downward adjustment of the conversion price for its convertible bonds due to stock prices falling below a specified threshold, which may impact investor decisions and the company's financial strategy [2][8]. Convertible Bond Issuance - The company issued a total of 4.4 million convertible bonds with a face value of 100 RMB each, raising a total of 440 million RMB, with a maturity period from June 28, 2022, to June 27, 2028 [2][3]. - The initial conversion price was set at 48.23 RMB per share, which was adjusted to 48.09 RMB on June 6, 2023, and will further adjust to 48.02 RMB on July 4, 2024, and to 47.95 RMB on July 2, 2025, due to annual equity distribution plans [3][4]. Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the company's stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [5][6]. - The potential trigger for this adjustment is set to begin on November 3, 2025, with a threshold price of 40.76 RMB per share [8]. Adjustment Procedure - If the company decides to adjust the conversion price, it will announce the details, including the adjustment range and the record date for shareholders, through the Shanghai Stock Exchange [7].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-066 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于"洁特转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025 年 11 月 3 日至 2025 年 11 月 14 日，广州洁特生物过滤股份有限公 司股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发转股价格 向下修正条件。若未来触发转股价格向下修正条款，公司董事会将召开会议决定 是否行使"洁特转债"转股价格的向下修正权利，并及时履行信息披露义务。 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 的有关规定，广州洁特生物过滤股份有限公司（以下简称"公司"）可能触发可转 换公司债券（以下简称"可转债"）转股价格向下修正条件的相关情况如下： 一、可转债发行上市情况 经上海证券交易所自律监管决定书（[20 ...

Core Points - Jiet Bio announced that from November 3 to November 14, 2025, its stock has closed below 85% of the current conversion price for 10 trading days, which is expected to trigger the downward adjustment of the conversion price [1] - If the downward adjustment clause for "Jiet Convertible Bonds" is triggered, the company's board will convene to decide whether to exercise the downward adjustment rights and will fulfill its information disclosure obligations in a timely manner [1]